Search
MSK researchers and collaborators have developed a new type of CAR T cell designed to attack a cell surface protein called uPAR — allowing them to target both tumors and cancer-supporting cells in the tumor microenvironment.
Today MSK issued a statement regarding its financial results for its fiscal year 2025.
A rare form of stomach cancer caused by an inherited gene mutation can be avoided by having the stomach removed — and many people can adjust to life afterward.
Learn about MSK’s Adolescent and Young Adult program, which is uniquely positioned to help patients like Danielle Leventhal.
Five Memorial Sloan Kettering (MSK) faculty were named today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy Class of 2022.
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the American Association for Cancer Research (AACR) Annual Meeting on April 8-13 in New Orleans, La.
Dr. Diane Reidy-Lagunes speaks with Dr. John Mulhall, Director of the Male Sexual and Reproductive Medicine Program at MSK and editor-in-chief of The Journal of Sexual Medicine, to discuss the impacts of cancer and its treatment on men’s sexual health.
Learn why Bobby Logan chose active surveillance for his prostate cancer, and how he was successfully treated after his tumor changed.
A new study is challenging the perception that mesothelioma affects only older men. Learn why MSK experts say the medical community should be aware of this rare cancer's early symptoms.
Learn about the clinical trials and research at MSK that led to FDA approvals in 2025, expanding treatment options for a range of different cancers.